Search Results for: Majority of Oncology Clinical Trials
Articles
February 14, 2018
Majority of Oncology Clinical Trials in China Failed to Meet Enrolment Targets February 14, 2018
The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December...
March 16, 2018
Majority of Clinical Trials Planned in 2018 Belong to Oncology March 16, 2018
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy areafor clinical trialsplanned to be initiated in 2018…
March 13, 2018
Majority of Clinical Trials Planned in 2018 Belong to Oncology March 13, 2018
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to...
April 9, 2024
Essential Pharma Acquires Renaissance Pharma With its Clinical-Stage Immunotherapy April 9, 2024
Essential Pharma recently announced it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance...
November 6, 2023
TriSalus Life Sciences Presents Late-Breaking Phase 1 Liver Metastasis Data; Supports Development of Innovative Immuno-oncology Approach for Liver & Pancreas Indications November 6, 2023
TriSalus Life Sciences Inc. recently presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of...
June 29, 2023
Urica Therapeutics Announces Topline Data From Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the US June 29, 2023
Urica Therapeutics, Inc. recently announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the...
February 27, 2023
IMUNON & Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination With Avastin in Advanced Ovarian Cancer February 27, 2023
IMUNON, Inc. and Break Through Cancer recently announced the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001...
November 16, 2022
Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1b Trial November 16, 2022
Monopar Therapeutics Inc. recently released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft...
September 1, 2022
Vaxart Announces Positive Top-line Phase 2 Clinical Study Data Demonstrating Safety & Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate September 1, 2022
Vaxart, Inc. recently reported positive top-line data from the first part of a planned two-part Phase 2 study of its...
May 31, 2022
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the US May 31, 2022
Fortress Biotech, Inc. recently announced its subsidiary company, UR-1 Therapeutics, Inc., dosed the first patient in a Phase 1 clinical...
April 11, 2022
Context Therapeutics Announces Encouraging Preclinical Data From Two Programs April 11, 2022
Context Therapeutics Inc. recently announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone...
March 30, 2022
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development March 30, 2022
Qualigen Therapeutics, Inc. recently announced it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead...
December 16, 2021
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected With HIV & CMV December 16, 2021
Fortress Biotech, Inc. and its partner company, Helocyte, Inc., recently announced a Phase 2 double-blind, randomized, placebo-controlled clinical trial has...
June 9, 2021
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-Targeting TriTAC HPN424 June 9, 2021
Harpoon Therapeutics, Inc. recently presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in...
June 26, 2019
Ziopharm Oncology Completes Enrollment of Phase 1 Combination Trial June 26, 2019
Ziopharm Oncology, Inc. recently announced completion of enrollment of the third cohort of a Phase 1 clinical trial evaluating Controlled...
June 19, 2019
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio With Acquisition June 19, 2019
Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group (GBG), recently announced that it has expanded...
October 9, 2017
NANOBIOTIX Plans to Conduct First Clinical Trial October 9, 2017
Nanobiotix recently announced its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed...
November 29, 2016
Mustang Bio Presents Clinical & Preclinical Data on MB-101 for Treatment of Glioblastoma November 29, 2016
Mustang Bio, Inc., a Fortress Biotech company, recently announced that Phase I clinical data and preclinical data on its MB-101...
September 27, 2016
Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration September 27, 2016
Bristol-Myers Squibb Company and Nektar Therapeutics recently announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's...
September 18, 2016
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen September 18, 2016
Geron Corporation recently provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase...
